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Background: Abnormal lipids is one of the critical risk factors for myocardial infarction (MI), however the role of
genetic variants in lipid metabolism-related genes on MI pathogenesis still requires further investigation. We herein
genotyped three SNPs (LRP6 rs2302685, LDLRAP1 rs6687605, SOAT1 rs13306731) in lipid metabolism-related genes,
aimed to shed light on the influence of these SNPs on individual susceptibility to MI.
Methods: Genotyping of the three SNPs (rs2302685, rs6687605 and rs13306731) was performed in 285 MI cases
and 650 control subjects using polymerase chain reaction–ligation detection reaction (PCR–LDR) method. The
association of these SNPs with MI and lipid profiles was performed with SPSS software.
Results: Multivariate logistic regression analysis showed that C allele (OR = 1.62, P = 0.039) and the combined CT/CC
genotype (OR = 1.67, P = 0.035) of LRP6 rs2302685 were associated with increased MI risk, while the other two SNPs
had no significant effect. Further stratified analysis uncovered a more evident association with MI risk among
younger subjects (≤60 years old). Fascinatingly, CT/CC genotype of rs2302685 conferred increased LDL-C levels
compared to TT genotype (3.0 mmol/L vs 2.72 mmol/L) in younger subjects.
Conclusions: Our data provides the first evidence that LRP6 rs2302685 polymorphism is associated with an
increased risk of MI in Chinese subjects, and the association is more evident among younger individuals, which
probably due to the elevated LDL-C levels.
Keywords: LRP6, Single nucleotide polymorphism, Myocardial infarction, RiskBackground
Myocardial infarction (MI) is a leading cause of death
and morbidity worldwide, which is a main manifestation
of coronary artery disease (CAD). Previous studies and
clinical trials have established multiple risk factors con-
tributing to the pathogenesis of MI, including obesity,
hypercholesterolemia, smoking, alcohol intake, diabetes,
hypertension, physical inactivity and psychosocial situation
[1-3]. Among these, hypercholesterolemia arising from
abnormal lipid metabolism has been considered to be
one of the most key risk factors for MI [4,5]. What’s more,
apart from above modifiable risk factors, a growing body
of studies have demonstrated close associations of genetic* Correspondence: xiongxingdong@126.com
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unless otherwise stated.variants in candidate genes with the risk of MI, suggesting
that host genetic backgrounds exert critical roles on MI
pathogenesis as well [6-8].
Low density lipoprotein receptor-related protein 6
(LRP6), a member of the LRP family of type I trans-
membrane proteins, functions as a co-receptor with
Frizzled proteins for Wnt ligands, and thus plays a crit-
ical role in the regulation of multiple cellular processes,
and the development of many human diseases [9-11].
Moreover, accumulating evidences have recently linked
LRP6 genetically to early coronary artery disease and
abnormal lipids including hypercholesterolemia [12-14].
Five functional mutations (K82N, S488Y, P1066T, P1206H
and I1264V) within LRP6 gene have been identified in
CAD patients, which might be contributing factors for
CAD through significantly reduction in both LRP6 protein
level and Wnt signal activity [15]. Another mutation in
LRP6 (R611C) has been identified in an Iranian familyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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syndrome (hyperlipidemia, hypertension and diabetes),
and osteoporosis [16], which significantly promoted
PDGF-dependent vascular smooth muscle cells (VSMCs)
proliferation compared to wild-type LRP6 [17]. Thus it
was reasonable to speculate that LRP6 might probably play
an important role in MI pathogenesis.
Low density lipoprotein receptor adaptor protein 1
(LDLRAP1) interacts with the cytoplasmic tail of LDL
receptor and exerts a crucial role on LDL uptake via
promoting LDL receptor clustering into clathrin-coated
pits [18-21]. In addition, mutations in LDLRAP1 gene
cause familial hypercholesterolemia (FH) characterized
with severe hypercholesterolemia and premature coronary
artery disease [22,23]. Sterol O-acyltransferase 1 (SOAT1)
is also named acyl-coenzyme A: cholesterol acyltransferase
(ACAT), which esterifies cholesterol in a variety of tissues
[24]. Previous studies have demonstrated that SOAT1 was
involved in the formation of atherosclerotic plaques, and
thus might be a promising target for atherosclerosis and
hypercholesterolemia treatment [25,26]. In spite of the
close association between these two genes and hyperchol-
esterolemia, the effects of LDLRAP1 and SOAT1 polymor-
phisms on hypercholesterolemia and CAD remain largely
unknown.
Single nucleotide polymorphism (SNP) has been estab-
lished to influence individual susceptibility for numerous
human diseases. A plethora of evidences have suggested
that SNPs within the lipid metabolism-related genes might
potentially contribute to MI risk [27-30]. Nonetheless, the
genetic causes and underlying molecular mechanisms of
these candidate genes for MI are still far to be elucidated.
Thus, we herein conducted a case–control study to inves-
tigate the association of the three SNPs in the lipid
metabolism-related genes (rs2302685 in LRP6, rs6687605
in LDLRAP1 and rs13306731 in SOAT1) with the risk of
MI. Our data revealed that the C allele of rs2302685 in
LRP6 has a significant association with an increased risk




285 MI patients and 650 control subjects were consecu-
tively recruited from the First People’s Hospital of Foshan
(Foshan, China) and the Affiliated Hospital of Guangdong
Medical College (Zhanjiang, China) from March 2011 to
February 2013. The diagnosis of MI was based on typical
electrocardiographic changes and on increases in the
serum cardiac markers, such as creatinine kinase, aspar-
tate aminotransferase, lactate dehydrogenase and troponin
T. The diagnosis was confirmed by the identification of
the responsible stenosis in any of the major coronary ar-
teries or in the left main trunk by coronary angiography.Subjects with a history of hematologic, neoplastic,
renal, liver, or thyroid diseases were excluded. The un-
affected controls were judged to be free of MI by ques-
tionnaires, medical history, clinical examination and
electrocardiography.
All subjects enrolled in this study were genetically unre-
lated ethnic Han Chinese. Each subject was interviewed to
collect information on demographic data and risk factors
related to MI after obtaining the informed consent. The
study was approved by the Medical Ethics Committee of
the First People’s Hospital of Foshan and the Affiliated
Hospital of Guangdong Medical College.
Biochemical parameters analysis
The blood sample drawn from each subject was centri-
fuged at 2000 × g for 15 min immediately after collection
and stored at −80°C. The levels of plasma total cholesterol
(TC), triglyceride (TG), high density lipoprotein choles-
terol (HDL-C), and low density lipoprotein cholesterol
(LDL-C) were measured enzymatically using a chemistry
analyzer (Olympus, Japan). Glucose was analyzed by the
glucose oxidase method with an Abbott V/P Analyzer
(Abbott Laboratories, USA).
DNA extraction
Genomic DNA was extracted from peripheral whole
blood by TIANamp blood DNA extraction kit (TianGen
Biotech, Beijing, China) according to the manufacturer’s
instructions. All DNA samples were dissolved in water
and stored at −20°C until use.
Genotyping
SNPs genotyping were performed utilizing polymerase
chain reaction-ligase detection reaction (PCR-LDR)
method (Shanghai Biowing Applied Biotechnology Com-
pany), as described in our previous study [31]. The se-
quence of primers and probes were listed in Additional
file 1: Table S1.
Statistical analysis
All the three SNPs were tested for confirmation with
Hardy-Weinberg expectations by a goodness-of-fit χ2
test among the control subjects. Quantitative variables
were expressed as mean ± standard deviation (SD), and
qualitative variables were expressed as percentages. The
differences of the demographic characteristics between
the cases and controls were estimated using the χ2 test
(for categorical variables) and Student’s t test (for con-
tinuous variables).
Multivariate association analyses with MI risk, geno-
type frequencies were assessed by means of multivariate
methods based on logistic regression analysis, the odds
ratios (ORs) and 95% confidence intervals (CIs) for the
effect of SNPs on MI risk adjusted by age, sex, smoking,
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Association analyses between SNPs and blood lipid pro-
files were performed by one-way analysis of variance
(ANOVA). The statistical analyses were performed using
the SPSS software (version 21). A P value of less than 0.05
was used as the criterion of statistical significance.
Results
Characteristics of the study population
The characteristics of MI cases and control subjects
were listed in Table 1. No statistically significant differ-
ence between cases and controls was observed in terms
of age. In the lipid profiles comparison, TG and LDL-C
were significantly higher in MI patients than in controls
(P < 0.001, P < 0.001, respectively), whereas serum HDL-C
levels were significantly higher among controls (P < 0.001).
Besides, the average fasting plasma glucose (FPG) in
MI cases was significantly higher than that of the con-
trols (P < 0.001). MI cases had higher levels of systolic
blood pressure, diastolic blood pressure; the preva-
lence of smokers, alcohol consumers, and individuals
with hypertension, diabetes or hyperlipidemia was sig-
nificantly higher among the MI patients. In addition,
the number of female subjects in MI cases was much
lower than the male subjects. In all, these data demon-
strated that male gender, smoking, alcohol intake, hyper-
tension, hyperlipidemia and diabetes mellitus were the
important risk factors for MI development in Chinese
population.
Multivariate associations of three SNPs with the risk of MI
Three SNPs (rs2302685 in LRP6, rs6687605 in LDLRAP1
and rs13306731 in SOAT1) were genotyped in 285 MITable 1 The characteristics of MI cases and controls
Variable Controls (n = 650) Cases (n =285) P-valuea
Age (years) 61.61 ± 12.22 62.07 ± 11.99 0.591
Sex (male) 377 (58.0%) 221 (77.5%) <0.001b
Smoking 168 (25.8%) 171 (60.0%) <0.001
Drinking 94 (14.5%) 77 (27.0%) <0.001
Hypertension 233 (35.8%) 179 (62.8%) <0.001
Diabetes 105 (16.2%) 136 (47.7%) <0.001
Hyperlipidemia 245 (37.7%) 201 (70.5%) <0.001
Systolic BP (mm Hg) 132.53 ± 18.98 140.02 ± 19.16 <0.001
Diastolic BP (mm Hg) 72.86 ± 10.47 75.66 ± 11.56 <0.001
FPG (mmol/L) 5.81 ± 1.91 6.64 ± 1.72 <0.001
Triglycerides (mmol/L) 1.49 ± 0.82 2.06 ± 0.97 <0.001
Total cholesterol
(mmol/L)
4.62 ± 1.16 4.71 ± 1.21 0.242
LDL cholesterol (mmol/L) 2.63 ± 0.92 3.03 ± 0.97 <0.001
HDL cholesterol (mmol/L) 1.37 ± 0.67 1.18 ± 0.36 <0.001
aTwo-sided chi-square test or independent-samples t-test.
bP values under 0.05 were indicated in bold font.patients and 650 control subjects. The primary informa-
tion for rs2302685, rs6687605 and rs13306731 polymor-
phisms was listed in Table 2. Minor allele frequency
(MAF) of all three SNPs in our controls was similar to
MAF for Chinese in HapMap database (Table 2). All the
genotype frequency distributions of the three SNPs in
our control subjects followed Hardy-Weinberg equilib-
rium proportions (all P values ≥ 0.10, Table 2).
The allele and genotype distributions of the three SNPs
in the cases and the controls were shown in Table 3. From
the allelic association analysis, we found only rs2302685
showed statistical significance and C allele was associated
with a significantly increased risk of MI (OR = 1.62, 95%
CI = 1.03-2.55, P = 0.039, Table 3). In addition, the com-
bined CT/CC genotype exhibited an increased risk of MI
as well (OR = 1.67, 95% CI = 1.04-2.67, P = 0.035, Table 3),
compared to TT genotype. These data indicated that LRP6
SNP rs2302685 was associated with MI risk, and that indi-
viduals carrying C allele might have significantly increased
MI susceptibility. However, we did not find any association
between rs6687605 or rs13306731 and the risk of MI
(Table 3).Stratification analyses of LRP6 rs2302685 polymorphism
and risk of MI
We further evaluated the alleles or genotypes of LRP6
rs2302685 and MI susceptibility after stratifying the
subjects by age, sex, status of smoking or drinking.
Stratification analyses by age (≤60 or > 60 years old) re-
vealed that the increased risk of MI was more evident
among younger subjects (≤60 years old) carrying C al-
lele (Table 4, OR = 2.46, 95% CI = 1.20-5.03, P = 0.014)
or the combined CT/CC genotype (Table 4, OR = 2.46,
95% CI = 1.19-5.06, P = 0.015), whereas no significant
association was observed from the group older than 60
years old (Table 4). No more evident association be-
tween LRP6 rs2302685 polymorphism and risk of MI
was observed among subgroups by sex, status of smok-
ing or drinking (data not shown).Table 2 Primary information for rs2302685, rs6687605
and rs13306731 SNPs
Genotyped SNPs rs2302685 rs6687605 rs13306731
Chr Pos (Genome Build 104.0) 12301898 25889632 179320578
Gene LRP6 LDLARP1 SOAT1
MAFa for Chinese (CHB) in
HapMap
0.138 0.476 0.354
MAF in our controls (n = 650) 0.064 0.419 0.291
P Value for HWEb test in our
controls
0.670 0.100 0.180
aMAF: minor allele frequency.
bHWE: Hardy–Weinberg equilibrium.









No. (%) No. (%)
LRP6 rs2302685
T 1217 (93.6) 524 (91.9) 1.00 -
C 83 (6.4) 46 (8.1) 1.62 (1.03-2.55) 0.039b
TT 569 (87.5) 240 (84.2) 1.00 -
CT + CC 81 (12.5) 45 (15.8) 1.67 (1.04-2.67) 0.035
LDLRAP1 rs6687605
C 545 (41.9) 233 (40.9) 1.00 -
T 755 (58.1) 337 (59.1) 1.00 (0.78-1.27) 0.986
CC 104 (16.0) 46 (16.1) 1.00 -
CT + TT 546 (84.0) 239 (83.9) 1.04 (0.67-1.63) 0.854
SOAT1 rs13306731
A 922 (70.9) 403 (70.7) 1.00 -
G 378 (29.1) 167 (29.3) 1.07 (0.83-1.39) 0.584
AA 334 (51.4) 142 (49.8) 1.00 -
GA + GG 316 (48.6) 143 (50.2) 1.04 (0.74-1.44) 0.84
aAdjusted for age, sex, smoking, drinking, hypertension, diabetes and
hyperlipidemia.
bP values under 0.05 were indicated in bold font.
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polymorphism and LDL-C levels
In order to probe into the potential explanation to the
enhanced effects of LRP6 rs2302685 polymorphism on
MI risk among younger subjects (≤60 years old), we fur-
ther analyzed the association between LRP6 rs2302685
polymorphism and LDL-C, HDL-C, TC and TG levels.
Though none of the above lipids profile exhibited signifi-
cant association with LRP6 rs2302685 polymorphism
among total subjects (data not shown), CT/CC genotypeTable 4 Multivariate associations of the rs2302685 in
LRP6 gene with the risk of MI by further stratification
for age
Type Controls no. (%) Cases no. (%) OR (95% CI)a P-valuea
≤60 y n = 297 n = 130
T 553 (93.1) 233 (89.6) 1.00 -
C 41 (6.9) 27 (10.4) 2.46 (1.20-5.03) 0.014b
TT 256 (86.2) 104 (80.0) 1.00 -
CT + CC 41 (13.8) 26 (20.0) 2.46 (1.19-5.06) 0.015
> 60 y n = 353 n = 155
T 664 (94.1) 291 (93.9) 1.00 -
C 42 (5.9) 19 (6.1) 1.16 (0.62-2.19) 0.636
TT 313 (88.7) 136 (87.7) 1.00 -
CT + CC 40 (11.3) 19 (12.3) 1.22 (0.63-2.35) 0.557
aAdjusted for sex, smoking, drinking, hypertension, diabetes
and hyperlipidemia.
bP values under 0.05 were indicated in bold font.of rs2302685 conferred 0.28 mmol/L increase in LDL-C
levels compared to TT genotype (3.00 mmol/L vs 2.72
mmol/L, P = 0.047) in younger subjects, whereas no sig-
nificant association was observed between rs2302685
and HDL-C, TC and TG levels (Table 5). Thus, the re-
sults indicated that the increased risk of LRP6 rs2302685
polymorphism in MI was more evident among younger
subjects might be probably due to the elevated LDL-C
levels.
Discussion
The principal pathogenesis of MI is the disruption of
coronary atherosclerotic plaques [32], which caused by
both individual’s genetic makeup and various environ-
mental factors. Previous studies have demonstrated the
effects of LRP6 in early coronary artery disease and ab-
normal blood lipids including hypercholesterolemia
[12-14], indicating the important role of LRP6 in the MI
development. Nonetheless, the association between SNPs
in LRP6 gene and MI risk is still largely unknown. In this
study, we performed a genetic association analysis on the
three SNPs (rs2302685 in LRP6, rs6687605 in LDLRAP1
and rs13306731 in SOAT1), and revealed that the LRP6
rs2302685 polymorphism was associated with increased
risk of MI in a Chinese Han population, and the associ-
ation was more remarkable among younger subjects (≤60
years old), which might potentially due to the enhanced
LDL-C levels. Taken together, our study suggested that
LRP6 rs2302685 might play an important role in the MI
pathogenesis.
Though rs2302685 has been considered as a common
functional LRP6 polymorphism, and is significantly asso-
ciated with several human diseases such as Alzheimer’s
disease [33], the effects of this polymorphism on MI risk
is still unknown. Nonetheless, Sarzani et al. has reported
that the rs2302685 was strongly related to carotid artery
atherosclerosis (CAA) in hypertensive patients, indicating
that C allele of LRP6 rs2302685 might be an independent
risk factor for CAA (OR = 2.08, 95% CI = 1.27-3.41, P =
0.003) [34]. Carotid artery atherosclerosis is closely as-
sociated with arterial cardiovascular events, and is a
strong predictor of future myocardial infarction, which
might share common risk factors [35,36]. Our data that
rs2302685 endowed C allele carriers with significant
increased MI risk was in consistent with the results
from the above association analysis between rs2302685
and CAA.
Our stratified analyses revealed that the increased risk
of LRP6 rs2302685 polymorphism in MI was more evi-
dent among younger subjects (≤60 years old), whereas
no significant association was observed from the group
older than 60 years old (Table 4). In addition, LRP6
rs2302685 only exhibited an association with elevated
LDL-C levels in younger individuals, but not in total or
Table 5 ANOVA analysis of the association between rs2302685 in LRP6 gene and the LDL-C, HDL-C, TC and TG levels
by further stratification for age
Variable ≤60 > 60
TT CT + CC P-valuea TT CT + CC P-valuea
LDL cholesterol (mmol/L) 2.72 ± 1.00 3.00 ± 1.04 0.047b 2.76 ± 0.91 2.63 ± 0.86 0.323
HDL cholesterol (mmol/L) 1.36 ± 0.83 1.31 ± 0.40 0.658 1.28 ± 0.39 1.29 ± 0.36 0.831
Total cholesterol (mmol/L) 4.65 ± 1.18 4.93 ± 1.24 0.077 4.63 ± 1.17 4.37 ± 1.04 0.103
Triglycerides (mmol/L) 1.79 ± 1.04 1.68 ± 1.00 0.415 1.57 ± 0.77 1.56 ± 0.73 0.965
aTwo-sided chi-square test or independent-samples t-test.
bP values under 0.05 were indicated in bold font.
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level exposure to environmental risk factors in older in-
dividuals may account for these. The potential risk of
MI in older subjects is more likely due to the aging ef-
fects rather than direct genetic effects. Thus, the LRP6
rs2302685 polymorphism might be more influential in
early-onset MI, which was similar as the effects of LRP6
R611C variant on early-onset CAD development in an
Iranian family [16].
Previous investigations have demonstrated that LRP6,
as a component of LDL cholesterol trafficking complex,
was involved in direct LDL uptake [37]; and the elevated
LDL-C levels in LRP6 R611C mutation carriers was
likely due to the reduced LDL clearance capacity [16].
Moreover, Tomaszewsk et al. unveiled that T allele of
LRP6 rs10845493 polymorphism was associated with
0.14 mmol/L increase in LDL-C levels (SE = 0. 05, P =
0.0038) [38]. In consistent with above findings, our data
revealed that the LDL-C levels of the individuals carry-
ing CT/CC genotype were higher than the TT genotype
carriers among younger individuals (≤60 years old)
(Table 5), which provided a reasonable explanation to
the enhanced effects of rs2302685 on MI pathogenesis
in younger subjects.
Several limitations herein in this case–control study
need to be addressed. First, the case subjects and con-
trols enrolled from hospitals may not represent the gen-
eral population. Nonetheless, the genotype distribution
of the controls was in Hardy-Weinberg equilibrium.
Second, the moderate sample size of our study limited
the statistical power, especially in the case subjects. Fi-
nally, further studies in different population could help
to verify the true significance of the association between
the rs2302685 polymorphism and the risk of MI. How-
ever, our observations provided valuable insights and
interesting information and might serve to guide future
studies in this area.
Conclusions
In aggregate, our study firstly unveiled that the C allele
of LRP6 rs2302685 was associated with an increased risk
of MI in a Chinese population, and the association was
more evident among younger subjects, which potentiallydue to the elevated LDL-C levels. Further studies with
larger sample size and in diverse ethnic populations are
required to confirm the general validity of our findings.
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